WuXi XDC Cayman Inc (HK:2268), a China-based global CRDMO (Contract Research, Development and Manufacturing Organisation) specialising in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), announced on Tuesday that it has entered into a Memorandum of Understanding (MOU) with AbTis, a South Korean ADC biotechnology company.

This partnership combines AbTis' proprietary site-selective conjugation platform AbClick and WuXi XDC's integrated discovery services and all-in-one development & manufacturing platform. The collaboration aims to accelerate ADC therapeutic innovation by integrating AbTis' technology into WuXi XDC's toolbox, while fostering new opportunities for global clients.

Through this agreement, WuXi XDC will incorporate AbTis' advanced site-selective conjugation technologies including the AbClick Platform, which utilises affinity peptide-assisted linkers to enable precise and efficient antibody-drug conjugation. Additionally, WuXi XDC will facilitate potential collaborations between AbTis and its client network. By enhancing CMC platform capabilities, both companies aim to empower clients to accelerate preclinical candidate selection, develop next-generation ADCs, and expedite CMC development timelines.